<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Novel Screen for Drug Discovery</AwardTitle>
<AwardEffectiveDate>07/01/2003</AwardEffectiveDate>
<AwardExpirationDate>06/30/2004</AwardExpirationDate>
<AwardTotalIntnAmount>100000.00</AwardTotalIntnAmount>
<AwardAmount>100000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Om P. Sahai</SignBlockName>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research (SBIR) Phase I project aims to develop a novel screen for drug discovery using gel microdrop (GMD) encapsulation technology, phage display technology and fluorescence activated cell sorting. In the last decade, phage display has evolved into a powerful tool for identifying "leads" for drug discovery. High affinity binders with sub-nanomolar dissociation constant have the greatest potential therapeutic value, however, they are difficult to isolate by biopanning. Currently, biopanning is effective at screening ~10 8 libraries in which the phage of interest is present at ~10 4 copies. Screening of highly diverse libraries  (&gt;10 9 ) in which phage of interest are typically present at  10-100 copies is difficult using such a method. Improvements have been made to increase the sensitivity of biopanning, but these improvements are limited to certain phage. Using a ~10 8 human growth hormone random library as a model library, Phase I research will develop a novel approach for screening phage libraries.&lt;br/&gt;&lt;br/&gt;The commercial application of this project will be in the area of drug discovery. The proposed technology will provide a controlled means of producing peptide and protein libraries that can be used to manufacture and refine molecules for use as therapeutics, and diagnostic and imaging reagents for diseases.</AbstractNarration>
<MinAmdLetterDate>06/13/2003</MinAmdLetterDate>
<MaxAmdLetterDate>12/08/2003</MaxAmdLetterDate>
<ARRAAmount/>
<AwardID>0318904</AwardID>
<Investigator>
<FirstName>Yevgenya</FirstName>
<LastName>Akselband</LastName>
<EmailAddress>yaks@onecell.com</EmailAddress>
<StartDate>06/13/2003</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>ONE CELL SYSTEMS, INC</Name>
<CityName>CAMBRIDGE</CityName>
<ZipCode>021399129</ZipCode>
<PhoneNumber>6178682399</PhoneNumber>
<StreetAddress>100 INMAN ST STE 200</StreetAddress>
<CountryName>United States</CountryName>
<StateName>Massachusetts</StateName>
<StateCode>MA</StateCode>
</Institution>
<FoaInformation>
<Code>0203000</Code>
<Name>Health</Name>
</FoaInformation>
<FoaInformation>
<Code>0510402</Code>
<Name>Biomaterials-Short &amp; Long Terms</Name>
</FoaInformation>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>9102</Code>
<Text>WOMEN, MINORITY, DISABLED, NEC</Text>
</ProgramReference>
<ProgramReference>
<Code>9181</Code>
<Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
</Award>
</rootTag>
